Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study - Individual Prediction and Prevention of Risks of Immunosuppressive Therapies in Transplantation Access content directly
Journal Articles Clinics and Research in Hepatology and Gastroenterology Year : 2021

Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study

Mohamed Hebbar

Domains

Cancer
Fichier principal
Vignette du fichier
S2210740120301571.pdf (625.04 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-04548045 , version 1 (22-07-2024)

Licence

Identifiers

Cite

Anthony Turpin, Thierry de Baere, Alexandra Heurgué, Karine Le Malicot, Isabelle Ollivier-Hourmand, et al.. Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study. Clinics and Research in Hepatology and Gastroenterology, 2021, 45 (2), pp.101464. ⟨10.1016/j.clinre.2020.05.012⟩. ⟨hal-04548045⟩
136 View
12 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More